Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Journal Title: Нирки - Year 2016, Vol 3, Issue 17
Abstract
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1–3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.
Authors and Affiliations
Ron T. Gansevoort, Mustafa Arici, Thomas Benzing
Keywords
Related Articles
- EP ID EP208332
- DOI 10.22141/2307-1257.3.17.2016.76538
- Views 106
- Downloads 0
Adsorptive-Rheological Properties of Blood Serum in Gouty Nephropathy
The aim and tasks of the study — to evaluate clinical-pathogenetic significance of changes in adsorptive rheological properties of blood serum (ARPB) in patients with different clinical courses of gouty nephropathy. Mate...
Pharmacogenetic Tests in the Nephrological Clinic
Selection of antihypertensive agents using pharmacogenetic tests and individual tolerance is essential in practical nephrology. Antihypertensive first-line drugs are metabolized through various CYP isoforms (CYP2D6, CYP2...
Acute Interstitial Nephritis: the Value of Morphological Diagnosis
The clinical case demonstrates the importance of and the need for kidney biopsy for morphological verification of the diagnosis to determine the therapeutic approach and management of patients with kidney disease.
Thyroid dysfunction and kidney diseases
Thyroid hormones provide normal functioning of the kidneys, which in turn are not only an organ for the metabolism and excretion of thyroid hormones but also serve as targets for the action of certain thyroid hormones. H...
Renin angiotensin-aldosterone system blockers: chronic kidney disease and cardiovascular risk
Reducing the risk of cardiovascular events is one of the most topical issues of modern medicine. Patients with chronic kidney disease stage 3 or lower, according to international guidelines, refer to the group with high...